Hanlon Investment Management adds St. Jude Medical (STJ) to its portfolio

St. Jude Medical (STJ) : Hanlon Investment Management added new position in St. Jude Medical during the most recent quarter end. The investment management firm now holds 61,225 shares of St. Jude Medical which is valued at $5,114,124 , the company said in a statement filed on Aug 2, 2016 with the SEC.St. Jude Medical makes up approximately 0.43% of Hanlon Investment Management’s portfolio.

Other Hedge Funds, Including , Parkside Financial Bank Trust boosted its stake in STJ in the latest quarter, The investment management firm added 13 additional shares and now holds a total of 65 shares of St. Jude Medical which is valued at $5,429.Sumitomo Mitsui Asset Management Company Ltd boosted its stake in STJ in the latest quarter, The investment management firm added 789 additional shares and now holds a total of 21,778 shares of St. Jude Medical which is valued at $1,808,445. St. Jude Medical makes up approx 0.05% of Sumitomo Mitsui Asset Management Company Ltd’s portfolio. Mar Vista Investment Partners sold out all of its stake in STJ during the most recent quarter. The investment firm sold 244,272 shares of STJ which is valued $20,284,347. Sphinx Trading Lp added STJ to its portfolio by purchasing 1,378 company shares during the most recent quarter which is valued at $112,583. St. Jude Medical makes up approx 0.90% of Sphinx Trading Lp’s portfolio.

St. Jude Medical closed down -0.39 points or -0.46% at $83.51 with 18,77,099 shares getting traded on Monday. Post opening the session at $83.8, the shares hit an intraday low of $83.4598 and an intraday high of $84 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, St. Jude Medical reported $1.06 EPS for the quarter, based on the information available during the earnings call on Jul 20, 2016. Analyst had a consensus estimate of $1.06. The company had revenue of $1562.00 million for the quarter, compared to analysts expectations of $1552.79 million. The company’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.

Many Wall Street Analysts have commented on St. Jude Medical. Company shares were Downgraded by Wedbush on Jul 15, 2016 to ” Neutral”, Firm has raised the Price Target to $ 84 from a previous price target of $70 .St. Jude Medical was Downgraded by Leerink Partners to ” Mkt Perform” on Jul 11, 2016. St. Jude Medical was Downgraded by Sun Trust Rbsn Humphrey to ” Neutral” on May 10, 2016.

St. Jude Medical Inc. develops manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management cardiovascular and atrial fibrillation therapy areas and interventional pain therapy and neurostimulation devices for the management of chronic pain and movement disorders. Its six principal product categories include tachycardia implantable cardioverter defibrillator (ICD) systems bradycardia pacemaker systems atrial fibrillation (AF) products (electrophysiology introducers and catheters advanced cardiac mapping navigation and recording systems and ablation systems) vascular products (vascular closure products pressure measurement guidewires optical coherence tomography (OCT) imaging products heart failure monitoring device and other vascular accessories) structural heart products and neuromodulation products (spinal cord stimulation and radiofrequency ablation to treat chronic pain and deep brain stimulation to treat movement disorders).

Leave a Reply

St. Jude Medical - Is it time to Sell?

Top Brokerage Firms are advising their investors on St. Jude Medical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.